Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies Respectively Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical ...
Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic ...
Palvella Therapeutics reports progress in clinical trials for QTORIN™ rapamycin, exceeding patient enrollment and anticipating significant results in upcoming years. Net loss of $8.2 million for the ...
Isolated from the Streptomyces hygroscopicus bacterium, rapamycin rose to prominence as an anti-fungal and anti-cancer drug and an immunosuppressant. Several decades later, it became the target ...
Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical Testing in a Number of Indications Including Microcystic Lymphatic Malformations and Venous Malformations, among others ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback